Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Mar-23 9:18 AM View:  | Crystal Roger Chief Executive Officer Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 87,106 | $20.00 | $1,742,120.00 | (100%) 87.11K to 0 | |
| 03-Mar-23 9:25 AM View: | Collard Craig A Director | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 55,822 | $20.00 | $1,116,440.00 | (100%) 55.82K to 0 | |
| 03-Mar-23 9:22 AM View: | Ruth Matthew R. Chief Commercial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Grant | 2,000 | -- | -- | 7% 29.92K to 31.92K | |
| 03-Mar-23 9:10 AM View: | Sinclair Michael Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 62,720 | $20.00 | $1,254,400.00 | (100%) 62.72K to 0 | |
| 03-Mar-23 9:13 AM View: | Skolnick Phil Chief Scientific Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 23,548 | $20.00 | $470,960.00 | (100%) 23.55K to 0 | |
| 03-Mar-23 9:27 AM View: | Silver Gabrielle Alison Director | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 23,343 | $20.00 | $466,860.00 | (100%) 23.34K to 0 | |
| 03-Mar-23 9:00 AM View: | Thomas Thomas T. Director | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 12,375 | $20.00 | $247,500.00 | (100%) 12.38K to 0 | |
| 03-Mar-23 9:16 AM View: | Ellison Mark Jason Heath Chief Development Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 18,751 | $20.00 | $375,020.00 | (62%) 30.43K to 11.68K | |
| 03-Mar-23 9:20 AM View: | Daly Richard J Director | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 7,800 | $20.00 | $156,000.00 | (100%) 7.8K to 0 | |
| 03-Mar-23 8:57 AM View: | O'Toole David D Chief Financial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Grant | 2,000 | -- | -- | 6% 34.25K to 36.25K | |
| 03-Mar-23 9:08 AM View: | MacDougall Ann L. Director | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 28,179 | $20.00 | $563,580.00 | (100%) 28.18K to 0 | |
| 03-Mar-23 9:22 AM View: | Ruth Matthew R. Chief Commercial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 31,916 | $20.00 | $638,320.00 | (100%) 31.92K to 0 | |
| 03-Mar-23 9:03 AM View: | Gorman Brian | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Grant | 2,000 | -- | -- | 6% 31.99K to 33.99K | |
| 03-Mar-23 9:16 AM View: | Ellison Mark Jason Heath Chief Development Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 9,680 | $20.00 | $193,600.00 | (83%) 11.68K to 2.0K | |
| 03-Mar-23 9:18 AM View: | Crystal Roger Chief Executive Officer Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Grant | 6,667 | -- | -- | 8% 80.44K to 87.11K | |
| 03-Mar-23 8:57 AM View: | O'Toole David D Chief Financial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 36,248 | $20.00 | $724,960.00 | (100%) 36.25K to 0 | |
| 03-Mar-23 9:10 AM View: | Sinclair Michael Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 27,450 | $20.00 | $549,000.00 | (30%) 90.17K to 62.72K | |
| 03-Mar-23 9:13 AM View: | Skolnick Phil Chief Scientific Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Grant | 2,000 | -- | -- | 9% 21.55K to 23.55K | |
| 03-Mar-23 9:03 AM View: | Gorman Brian | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 33,990 | $20.00 | $679,800.00 | (100%) 33.99K to 0 | |
| 03-Mar-23 9:16 AM View: | Ellison Mark Jason Heath Chief Development Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Grant | 2,000 | -- | -- | 7% 28.43K to 30.43K | |
| 03-Mar-23 9:16 AM View: | Ellison Mark Jason Heath Chief Development Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 2,000 | $20.00 | $40,000.00 | (100%) 2.0K to 0 | |
| 03-Mar-23 9:05 AM View: | Lorianne Masuoka K. Director | Opiant Pharmaceuticals, Inc. (OPNT) | 02-Mar-23 | Disposition | 4,000 | $20.00 | $80,000.00 | (100%) 4.0K to 0 | |
| 31-Jan-23 4:22 PM View: | Crystal Roger Chief Executive Officer Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jan-23 | Sale | 1,358 | $20.26 | $27,513.10 | (2%) 76.7K to 75.34K | |
| 31-Jan-23 4:19 PM View: | Skolnick Phil Chief Scientific Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jan-23 | Sale | 480 | $20.26 | $9,724.80 | (2%) 22.03K to 21.55K | |
| 31-Jan-23 4:20 PM View: | Gorman Brian | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jan-23 | Sale | 444 | $20.26 | $8,995.44 | (1%) 32.43K to 31.99K | |
| 31-Jan-23 4:17 PM View: | O'Toole David D Chief Financial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jan-23 | Sale | 541 | $20.26 | $10,960.70 | (2%) 34.79K to 34.25K | |
| 31-Jan-23 4:21 PM View: | Ellison Mark Jason Heath Chief Development Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jan-23 | Sale | 610 | $20.26 | $12,358.60 | (3%) 19.36K to 18.75K | |
| 09-Jan-23 5:16 PM View: | O'Toole David D Chief Financial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 09-Jan-23 | Sale | 415 | $20.20 | $8,383.00 | (1%) 35.2K to 34.79K | |
| 09-Jan-23 5:13 PM View: | Ellison Mark Jason Heath Chief Development Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 09-Jan-23 | Sale | 469 | $20.20 | $9,473.80 | (2%) 19.83K to 19.36K | |
| 09-Jan-23 5:09 PM View: | Crystal Roger Chief Executive Officer Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 09-Jan-23 | Sale | 1,183 | $20.20 | $23,896.60 | (2%) 77.88K to 76.7K | |
| 09-Jan-23 5:11 PM View: | Skolnick Phil Chief Scientific Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 09-Jan-23 | Sale | 369 | $20.20 | $7,453.80 | (2%) 22.4K to 22.03K | |
| 05-Jan-23 5:03 PM View: | O'Toole David D Chief Financial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 05-Jan-23 | Sale | 1,600 | $20.20 | $32,320.00 | (4%) 36.8K to 35.2K | |
| 05-Jan-23 4:59 PM View: | Gorman Brian | Opiant Pharmaceuticals, Inc. (OPNT) | 05-Jan-23 | Sale | 1,313 | $20.20 | $26,522.60 | (4%) 33.75K to 32.43K | |
| 05-Jan-23 5:07 PM View: | Ellison Mark Jason Heath Chief Development Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 05-Jan-23 | Sale | 1,806 | $20.20 | $36,481.20 | (8%) 21.64K to 19.83K | |
| 05-Jan-23 4:52 PM View: | Crystal Roger Chief Executive Officer Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 05-Jan-23 | Sale | 5,029 | $20.20 | $101,586.00 | (6%) 82.91K to 77.88K | |
| 05-Jan-23 4:56 PM View: | Skolnick Phil Chief Scientific Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 05-Jan-23 | Sale | 1,421 | $20.20 | $28,704.20 | (6%) 23.82K to 22.4K | |
| 21-Jul-22 4:08 PM View: | Ruth Matthew R. Chief Commercial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 20-Jul-22 | Sale | 1,084 | $10.62 | $11,512.10 | (3%) 31.0K to 29.92K | |
| 15-Jul-22 4:04 PM View: | Gorman Brian | Opiant Pharmaceuticals, Inc. (OPNT) | 14-Jul-22 | Sale | 691 | $11.16 | $7,711.56 | (2%) 34.44K to 33.75K | |
| 15-Jul-22 4:03 PM View: | Crystal Roger Chief Executive Officer Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 14-Jul-22 | Sale | 2,246 | $11.11 | $24,953.10 | (3%) 85.16K to 82.91K | |
| 15-Jul-22 4:05 PM View: | Skolnick Phil Chief Scientific Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 14-Jul-22 | Sale | 627 | $11.85 | $7,429.95 | (3%) 24.45K to 23.82K | |
| 15-Jul-22 4:06 PM View: | O'Toole David D Chief Financial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 14-Jul-22 | Sale | 779 | $11.10 | $8,646.90 | (2%) 37.58K to 36.8K | |
| 29-Jun-22 4:01 PM View: | Ruth Matthew R. Chief Commercial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jun-22 | Grant | 2,000 | -- | -- | 7% 29.0K to 31.0K | |
| 29-Jun-22 4:06 PM View: | Crystal Roger Chief Executive Officer Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jun-22 | Grant | 6,667 | -- | -- | 8% 78.49K to 85.16K | |
| 29-Jun-22 4:02 PM View: | Gorman Brian | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jun-22 | Grant | 2,000 | -- | -- | 6% 32.44K to 34.44K | |
| 29-Jun-22 4:03 PM View: | Skolnick Phil Chief Scientific Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jun-22 | Grant | 2,000 | -- | -- | 9% 22.45K to 24.45K | |
| 29-Jun-22 4:04 PM View: | O'Toole David D Chief Financial Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jun-22 | Grant | 2,000 | -- | -- | 6% 35.58K to 37.58K | |
| 29-Jun-22 4:07 PM View: | Ellison Mark Jason Heath Chief Development Officer | Opiant Pharmaceuticals, Inc. (OPNT) | 27-Jun-22 | Grant | 2,000 | -- | -- | 10% 19.64K to 21.64K | |
| 15-Jun-22 4:30 PM View: | Sinclair Michael Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 15-Jun-22 | Sale | 900 | $10.60 | $9,540.00 | (4%) 20.12K to 19.22K | |
| 14-Jun-22 4:51 PM View: | Silver Gabrielle Alison Director | Opiant Pharmaceuticals, Inc. (OPNT) | 14-Jun-22 | Grant | 2,000 | -- | -- | 9% 21.34K to 23.34K | |
| 15-Jun-22 4:30 PM View: | Sinclair Michael Director 10% Owner | Opiant Pharmaceuticals, Inc. (OPNT) | 14-Jun-22 | Sale | 7,225 | $10.90 | $78,752.50 | (26%) 27.34K to 20.12K |
